Investing.com – With the use of monoclonal antibodies developed by two US drug manufacturers, Eli Lilly and AbCeller, in experimental therapy, COVID-19 patients can clear the infection faster, potentially reducing or even preventing hospitalizations, CNBC writes.
Antibodies have been detected in blood samples taken from one of the first U.S. patients to recover from coronavirus. Currently, in addition to the already mentioned Eli Lilly, several companies are simultaneously developing antibodies to the virus: GlaxoSmithKline GSK and Regeneron Pharmaceuticals.
According to Eli Lilly, her antibody-based drug LY-CoV555 has helped reduce hospitalizations for coronavirus patients with mild to moderate symptoms. The trial involved 450 people who were given different doses of the drug, and only an average dose of 2800 mg contributed to the achievement of the study goal and a significant decrease in the presence of coronavirus cells (SARS-CoV-2) in the blood of patients after 11 days, while the lower and a large dose, 700 mg and 7000 mg, respectively, did not give any result.
Daniel Skowronski, Lilly's Chief Scientist and President of Lilly Research Laboratories, said that “interim data from BLAZE-1 studies suggest that LY-CoV555 antibodies, specifically directed against SARS-CoV-2, have a direct antiviral effect and may reduce hospital admissions. with COVID-19.
“The results confirm our belief that neutralizing antibodies can help fight the coronavirus,” he said.
In preparation, materials from CNBC were used